AMG176, another Mcl-1 inhibitor, is being tested in participants with relapsed or refractory multiple myeloma, and in patients with relapsed or refractory acute myeloid leukemia (NCT02675452 clinical study phase I) [57]. Here, MCL1 is linked to acute myeloid leukemia.